Carcinoid syndrome classification: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}{{AE}}{{Anum}}{{PSD}} | {{CMG}}{{AE}}{{Anum}}{{PSD}} | ||
==Overview== | ==Overview== | ||
Gastroenteropancreatic neuroendocrine tumors are classified based upon their origin from the embryonic divisions of the alimentary tract into foregut,midgut and hindgut tumours. | |||
==Classification== | ==Classification== | ||
Revision as of 15:31, 31 January 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Anum Gull M.B.B.S.[2]Parminder Dhingra, M.D. [3]
Overview
Gastroenteropancreatic neuroendocrine tumors are classified based upon their origin from the embryonic divisions of the alimentary tract into foregut,midgut and hindgut tumours.
Classification
- Gastroenteropancreatic neuroendocrine tumors are classified based upon their origin from the embryonic divisions of the alimentary tract:
- Foregut (bronchial, stomach)
- Midgut (small intestine, appendix, cecum)
- Hindgut (distal colon, rectum, genitourinary)
- GET-NETs produce a number of secretory products, resulting in a wide range of clinical symptoms.[1] [2][3]
- Midgut gastrointestinal tract NETs (GINETs) produce serotonin and other vasoactive substances that give rise to the typical carcinoid syndrome.
|
Carcinoid syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Carcinoid syndrome classification On the Web |
|
American Roentgen Ray Society Images of Carcinoid syndrome classification |
|
Risk calculators and risk factors for Carcinoid syndrome classification |
| Foregut | Midgut | Hindgut | |
|---|---|---|---|
| Location |
|
|
|
| Hormones produced |
|
|
Variable |
| Possibility of carcinoid syndrome | Rare, and atypical when it happens | Classic | Rare |
References
- ↑ Büyükaşık K, Arı A, Tatar C, Akçe B, Sevinç MM, Sarı S, Paşaoğlu E, Bektaş H (2017). "Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases". Turk J Surg. 33 (4): 279–283. doi:10.5152/UCD.2017.3685. PMID 29260133.
- ↑ Davies L, Weickert MO (2016). "Gastroenteropancreatic neuroendocrine tumours: an overview". Br J Nurs. 25 (4): S12–5. doi:10.12968/bjon.2016.25.4.S12. PMID 26911175.
- ↑ Oberg K, Castellano D (March 2011). "Current knowledge on diagnosis and staging of neuroendocrine tumors". Cancer Metastasis Rev. 30 Suppl 1: 3–7. doi:10.1007/s10555-011-9292-1. PMID 21311954.